Form 4: Director David Meek Reports uniQure Equity Transactions

Director David Meek acquired restricted share units and stock options while selling shares to cover tax obligations.

Summary

• Director David D. Meek received a grant of 7,550 restricted share units (RSUs) on June 10, 2026.
• Director Meek was granted 13,980 stock options with an exercise price of $26.82 on June 10, 2026.
• A total of 1,993 shares were sold on June 11, 2026, at a weighted average price of $27.06 to satisfy tax withholding requirements.
• Following these transactions, the director holds 39,747 ordinary shares and 13,980 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation and tax compliance activities.

Positives

• Director maintains a significant equity stake of 39,747 shares in the company.
• Equity grants align director incentives with long-term shareholder value.

Negatives

• The sale of 1,993 shares, while non-discretionary, reduces the director's total direct holdings.

Risks

• Vesting of RSUs and stock options is contingent upon the director's continued relationship with the issuer.

Future Outlook

The RSUs and stock options vest 100% on the first anniversary of the grant date (June 10, 2027), subject to continued service.

Industry Context

StockSavvy.ai notes that routine equity grants and tax-related sales by directors are standard corporate governance practices in the biotechnology sector to maintain executive retention and alignment.

Comparison to Industry Standards

• The use of automatic sell-to-cover transactions for tax obligations is a standard practice among public biotech companies.
• One-year cliff vesting for director equity is consistent with typical industry compensation structures.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and related to tax obligations.

Next Steps

• Vesting of 7,550 RSUs on June 10, 2027.
• Vesting of 13,980 stock options on June 10, 2027.

Key Dates

Keywords

uniQure, QURE, Form 4, Insider Trading, Equity Compensation, Biotech